Volume | 1,417,986 |
|
|||||
News | - | ||||||
Day High | 0.80 | Low High |
|||||
Day Low | 0.73 |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
Spruce Biosciences Inc | SPRB | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
0.73 | 0.73 | 0.80 | 0.7859 | 0.74 |
Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
---|---|---|---|---|---|
2,886 | 1,417,986 | $ 0.7726491 | $ 1,095,606 | - | 0.6786 - 5.95 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
19:59:40 | formt | 125 | $ 0.8022 | USD |
Spruce Biosciences Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
32.16M | 40.71M | - | 0 | -46.18M | -1.13 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Spruce Biosciences News
Loading Messages....
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical SPRB Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 0.74 | 0.80 | 0.6786 | 0.7282521 | 2,147,364 | 0.0622 | 8.41% |
1 Month | 5.37 | 5.95 | 0.6786 | 1.31 | 2,952,921 | -4.57 | -85.06% |
3 Months | 2.70 | 5.95 | 0.6786 | 1.81 | 1,246,987 | -1.90 | -70.29% |
6 Months | 2.23 | 5.95 | 0.6786 | 1.80 | 664,599 | -1.43 | -64.03% |
1 Year | 2.27 | 5.95 | 0.6786 | 1.88 | 388,587 | -1.47 | -64.66% |
3 Years | 15.96 | 17.99 | 0.6786 | 3.50 | 628,234 | -15.16 | -94.97% |
5 Years | 17.00 | 35.60 | 0.6786 | 3.84 | 555,510 | -16.20 | -95.28% |
Spruce Biosciences Description
Spruce Biosciences Inc is a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders. The company is developing its wholly-owned product candidate, tildacerfont, as the potential first non-steroidal therapy to offer improved disease control and reduce steroid burden for patients suffering from classic congenital adrenal hyperplasia (CAH). |